BDR Pharma launches generic antibiotic combo of ceftazidime and avibactum

BDR Pharmaceuticals, a leading pharmaceutical company, has launched a new generic antibiotic under brand name Xavitaz which is a combination of ceftazidime and avibactum. The drug will be effective in treating gram negative infections (hospital-acquired & ventilator-associated pneumonia, intra-abdominal infections and complicated UTIs). Previously, only the imported version of the drug was available, which may have resulted in limited availability across various locations. Given the high demand for the drug, BDR is now launching a new antibiotic in his segment that will be easier to find for the treating physician. Xavitaz is a combination of 2g ceftazidime and 500mg avibactam, this combination is useful in treating resistant gram-negative infections, including those caused by pseudomonas aeruginosa and many ceftazidime resistant strains. Hospital-acquired and ventilator-associated pneumonia, two main types of community-acquired pneumonia (which is the most common type of pneumonia in India, affecting 4 million people per year and hospitalising 20 per cent of them). Intra-abdominal infections, along with two other syndromes, accounted for 7.7 million deaths worldwide, in 2019. Raheel Shah, director of business development, BDR Group, stated, "Ensuring that all patients have access to quality-produced, world-class treatment was the main reason for launching the drug in India. BDR Pharma has a vision of strengthening the R&D department and works in accordance with the needs of the people. We are extremely pleased with the launch of ceftazidime avibactum because it will add to the repertoire of physicians treating infections.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!